10-Q: Abpro Holdings Faces Delisting, Deepens Losses in Q2

Abpro Holdings, Inc. reported a significantly increased net loss in Q2 2025, alongside multiple Nasdaq delisting notices and a 'going concern' warning.

Summary

• Reported a net loss of $2,984 thousand for the three months ended June 30, 2025, compared to $2,440 thousand for the same period in 2024.
• Net loss for the six months ended June 30, 2025, significantly increased to $6,871 thousand from $1,804 thousand in the prior year period.
• Research and development expenses decreased by $0.5 million for the three months and $1.2 million for the six months ended June 30, 2025, primarily due to personnel furlough and reduced activities while raising capital.
• General and administrative expenses increased by $0.4 million for the three months and $1.2 million for the six months ended June 30, 2025, mainly due to public company operating costs, partially offset by headcount reduction.
• Received multiple notices from Nasdaq regarding non-compliance with minimum bid price ($1.00), Market Value of Publicly Held Shares ($15 million), and Market Value of Listed Securities ($50 million) requirements.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year.
• Cash balance as of June 30, 2025, was $2,014 thousand, insufficient to operate for at least 12 months.
• Received net proceeds of $1,840 thousand from the Second Convertible Note on June 23, 2025, which was fully converted in July 2025 into 11,024,725 shares of common stock.
• Subsequent to quarter-end, YA purchased additional common stock under the SEPA for an aggregate of $734 thousand in July and August 2025.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a significant increase in net losses, a critical 'going concern' warning, multiple Nasdaq delisting threats, and a substantial reduction in core R&D activities. While some capital was raised, it appears insufficient to address the underlying financial distress and operational slowdown.

Positives

• Net cash used in operating activities decreased by $1.1 million for the six months ended June 30, 2025, compared to the same period in 2024, primarily due to timing of payments and increased accounts payable.
• Secured additional funding through the Second Convertible Note ($1,840 thousand net proceeds) and subsequent share purchases under the SEPA ($734 thousand in July-August 2025).

Negatives

• Net loss significantly increased to $6,871 thousand for the six months ended June 30, 2025, from $1,804 thousand in the prior year.
• Accumulated deficit grew to $122,974 thousand as of June 30, 2025.
• Cash balance of $2,014 thousand as of June 30, 2025, is insufficient to fund operations for the next 12 months.
• Received Nasdaq notices for failing to meet minimum bid price ($1.00), Market Value of Publicly Held Shares ($15 million), and Market Value of Listed Securities ($50 million) requirements, risking delisting.
• Research and development activities were significantly reduced due to personnel furlough and the need to raise additional capital.
• Increased general and administrative expenses due to public company operating costs.
• Incurred a loss of approximately $0.6 million on the change in the fair value of embedded derivative liabilities for the three months ended June 30, 2025.
• Incurred a loss on the settlement of convertible notes of approximately $0.1 million for the three months ended June 30, 2025.
• Identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, insufficient controls for contractual obligations, and lack of formal written policies.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year.
• Failure to meet Nasdaq's continued listing requirements (minimum bid price, MVPHS, MVLS) could result in delisting, negatively impacting share price, liquidity, and future financing capabilities.
• Dependence on ability to raise additional capital through equity and debt financings, collaboration agreements, and research grants, with no assurance of success on acceptable terms.
• Potential for material dilution of ownership interest if additional capital is raised through equity or convertible debt securities.
• Restrictive covenants from debt financing or preferred equity financing could limit future actions.
• Relinquishing valuable rights to technologies, future revenue streams, or product candidates if funds are raised through collaborations or licensing arrangements.
• Inability to obtain funding could force delays, reductions, or elimination of research and development programs, product portfolio expansion, or commercialization efforts.
• Subject to risks and uncertainties common to early-stage biotechnology companies, including competitor development, dependence on key executives, protection of proprietary technology, and compliance with government regulations.
• Programs under development require significant additional R&D, preclinical/clinical testing, and regulatory approval, requiring substantial capital, personnel, and infrastructure.
• Uncertainty regarding realization of significant revenue from product sales, even if product development is successful.
• Ongoing legal disputes and accrued liabilities with a CRO vendor ($827 thousand), other vendors ($325 thousand), and MSK ($1,230 thousand), and a former director ($748 thousand claim).

Future Outlook

The company expects to incur substantial operating losses and negative cash flows for the foreseeable future as it advances product candidates. Clinical trials for ABP-102 are expected to initiate in the first half of 2026. The initiation of clinical trials for ABP-201 may depend on future funding availability. The company plans to seek additional funding through equity and debt financings, collaboration agreements, and research grants, but there is no assurance of obtaining such financing on acceptable terms.

Management Comments

• Management has concluded there is substantial doubt as to the Company's ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued.
• The overall decrease in research and development expenses was a result of the decrease in research and development activities while raising additional capital necessary to restart our research and development programs.
• The Company intends to monitor the market value of its listed securities and may, if appropriate, consider available options to regain compliance with Nasdaq listing requirements.

Industry Context

Abpro Holdings operates in the highly capital-intensive and risky biotechnology industry, focused on developing novel antibody therapeutics. The significant reduction in R&D activities due to funding constraints, coupled with substantial operating losses and Nasdaq delisting threats, indicates a challenging position for an early-stage company in this competitive sector. The reliance on external financing for clinical development is typical, but the current financial distress and compliance issues suggest a struggle to secure necessary capital, potentially hindering its ability to compete with more well-funded peers.

Comparison to Industry Standards

• The company's accumulated deficit of $122.974 million and recurring net losses are common for early-stage biotechnology companies, but the magnitude of the losses and the 'going concern' warning indicate a more severe financial position than many peers who manage to secure sufficient funding for their development pipelines.
• The significant reduction in R&D expenses due to personnel furlough is a critical red flag, suggesting a halt or severe slowdown in core development activities, which is atypical for a biotech company actively pursuing clinical trials unless it's a strategic pivot or a sign of severe financial distress. More stable biotech companies typically maintain or increase R&D as programs advance.
• The multiple Nasdaq listing deficiencies (minimum bid price, MVPHS, MVLS) are a strong indicator of underperformance compared to industry benchmarks for publicly traded biotech firms, which are expected to maintain certain market capitalization and share price levels to ensure investor confidence and liquidity. Companies like Moderna or BioNTech, while much larger, demonstrate the capital market access and valuation stability that Abpro lacks.
• The reliance on convertible notes and standby equity purchase agreements (SEPA) with significant dilution potential (e.g., conversion of notes into millions of shares at low prices) is a common financing mechanism for distressed or early-stage biotechs, but the terms often reflect a high cost of capital compared to more established companies that can access traditional equity or debt markets more favorably.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit from a contract research organization (CRO) vendor for approximately $700 thousand (as of January 24, 2024 judgment request) for unpaid installments under a settlement agreement. Outstanding balance was $827 thousand as of June 30, 2025.
• Accrued $325 thousand related to disputed invoices with other vendors.
• MSK demanded payments totaling $1,230 thousand for services under the terminated MSK License Agreement.
• Complaint received from a former director asserting a total of $748 thousand owed for consulting fees, bonuses, and unpaid promissory note principal and interest.

Related Party Transactions

• Promissory notes outstanding with ABI (a significant investor), an executive, and a former director.
• CEO Consulting Agreement signed on July 25, 2025, with BioCelsus International Inc., an entity wholly owned by the CEO, for an annual base fee of $300,000 and potential change of control payments.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises through equity issuances (e.g., SEPA conversions) and potential delisting from Nasdaq, which would reduce liquidity and likely depress share price.
• Employees (especially R&D personnel) have been on furlough, indicating job insecurity and potential impact on morale and talent retention.
• Creditors (vendors, former director) are involved in legal disputes over unpaid amounts, indicating potential for further litigation and financial strain on the company.
• Future patients could be impacted by delays or elimination of research and development programs if funding is not secured.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by September 29, 2025.
• Regain compliance with Nasdaq's Market Value of Publicly Held Shares (MVPHS) requirement by October 7, 2025.
• Regain compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement by October 7, 2025.
• Continue efforts to raise additional capital through equity and debt financings, collaboration agreements, and research grants.
• Initiate clinical trials for ABP-102 in the first half of 2026.
• Address material weaknesses in internal control over financial reporting, including segregation of duties, contractual obligation evaluation, and formal written policies.
• Engage in discussions with Mabwell regarding the disputed $3,300 thousand claim.
• Engage in discussions with a former director regarding the $748 thousand claim.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net losses, a critical 'going concern' warning, and a cash balance insufficient for 12 months of operations. Multiple Nasdaq delisting notices pose an immediate threat to liquidity and investor confidence. Research and development activities, crucial for a biotech company, have been significantly curtailed due to funding issues. The ongoing legal disputes and material weaknesses in internal controls further compound the risks. While some capital has been raised, it appears to be a stop-gap measure, and the long-term viability is highly uncertain. These factors collectively point to a very high-risk investment with significant downside potential.

Keywords

Biotechnology, Antibody Therapeutics, Immuno-oncology, Ophthalmology, Infectious Disease, Nasdaq Delisting, Going Concern, SEC Filing, Form 10-Q, Clinical Trials, ABP-102, ABP-201, Capital Raise, Convertible Notes, SEPA